Published in Genes Dev on September 15, 1999
Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med (2000) 9.78
Matrix-embedded cells control osteoclast formation. Nat Med (2011) 5.77
Trophic macrophages in development and disease. Nat Rev Immunol (2009) 5.37
Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature (2011) 4.57
Cancer to bone: a fatal attraction. Nat Rev Cancer (2011) 4.08
Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature (2010) 4.01
RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A (2000) 3.95
RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature (2010) 3.66
Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys (2008) 3.61
The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology (2005) 3.18
Retinoid-related orphan receptor gamma (RORgamma) is essential for lymphoid organogenesis and controls apoptosis during thymopoiesis. Proc Natl Acad Sci U S A (2000) 2.99
RANK signals from CD4(+)3(-) inducer cells regulate development of Aire-expressing epithelial cells in the thymic medulla. J Exp Med (2007) 2.91
Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev (2007) 2.82
NF-κB in immunobiology. Cell Res (2011) 2.61
B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease. Am J Pathol (2006) 2.56
The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Res Ther (2004) 2.54
A novel X-linked disorder of immune deficiency and hypohidrotic ectodermal dysplasia is allelic to incontinentia pigmenti and due to mutations in IKK-gamma (NEMO). Am J Hum Genet (2000) 2.48
Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis. EMBO J (2001) 2.37
Osteoimmunology: interactions of the bone and immune system. Endocr Rev (2008) 2.32
Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A (2001) 2.27
I{kappa}B kinase (IKK){beta}, but not IKK{alpha}, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J Exp Med (2005) 2.21
Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis. J Exp Med (2005) 2.21
Development of secondary lymphoid organs. Annu Rev Immunol (2008) 2.10
Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation. J Clin Invest (2013) 2.08
Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov (2012) 2.07
Disorders of bone remodeling. Annu Rev Pathol (2011) 2.05
Osteoimmunology and the effects of the immune system on bone. Nat Rev Rheumatol (2009) 2.01
Regulation of peripheral lymph node genesis by the tumor necrosis factor family member TRANCE. J Exp Med (2000) 1.93
Paget disease of bone. J Clin Invest (2005) 1.92
Inflammatory bone loss: pathogenesis and therapeutic intervention. Nat Rev Drug Discov (2012) 1.91
Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer. Endocr Rev (2013) 1.91
Tumor necrosis factor-α signaling in macrophages. Crit Rev Eukaryot Gene Expr (2010) 1.87
Inflammatory arthritis increases mouse osteoclast precursors with myeloid suppressor function. J Clin Invest (2012) 1.72
The association of Notch2 and NF-kappaB accelerates RANKL-induced osteoclastogenesis. Mol Cell Biol (2008) 1.70
RANKL synthesized by articular chondrocytes contributes to juxta-articular bone loss in chronic arthritis. Arthritis Res Ther (2012) 1.59
The Blimp1-Bcl6 axis is critical to regulate osteoclast differentiation and bone homeostasis. J Exp Med (2010) 1.59
TNF ligands and receptors--a matter of life and death. Br J Pharmacol (2002) 1.57
Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6. Mol Cell Biol (2002) 1.53
Impaired micro-RNA pathways diminish osteoclast differentiation and function. J Biol Chem (2008) 1.53
RANK-mediated amplification of TRAF6 signaling leads to NFATc1 induction during osteoclastogenesis. EMBO J (2005) 1.53
A genome-wide association study of myasthenia gravis. JAMA Neurol (2015) 1.52
NF-kappaB p100 limits TNF-induced bone resorption in mice by a TRAF3-dependent mechanism. J Clin Invest (2009) 1.52
Positive regulators of osteoclastogenesis and bone resorption in rheumatoid arthritis. Arthritis Res Ther (2011) 1.51
Estrogen-dependent and C-C chemokine receptor-2-dependent pathways determine osteoclast behavior in osteoporosis. Nat Med (2009) 1.50
Secondary lymphoid organs: responding to genetic and environmental cues in ontogeny and the immune response. J Immunol (2009) 1.47
Role of zeta PKC in B-cell signaling and function. EMBO J (2002) 1.45
Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity. J Clin Invest (2001) 1.45
Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. PLoS One (2011) 1.44
Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations. Am J Hum Genet (2008) 1.41
TRAF4 deficiency leads to tracheal malformation with resulting alterations in air flow to the lungs. Am J Pathol (2000) 1.40
Osteoimmunology: crosstalk between the immune and bone systems. J Clin Immunol (2009) 1.39
Role of RANKL and RANK in bone loss and arthritis. Ann Rheum Dis (2002) 1.35
The osteopetrotic mutation toothless (tl) is a loss-of-function frameshift mutation in the rat Csf1 gene: Evidence of a crucial role for CSF-1 in osteoclastogenesis and endochondral ossification. Proc Natl Acad Sci U S A (2002) 1.34
Requirement for the NF-kappaB family member RelA in the development of secondary lymphoid organs. J Exp Med (2002) 1.32
Osteoblast lineage-specific effects of notch activation in the skeleton. Endocrinology (2012) 1.32
Strength of TRAF6 signalling determines osteoclastogenesis. EMBO Rep (2005) 1.30
Biology of the RANKL-RANK-OPG System in Immunity, Bone, and Beyond. Front Immunol (2014) 1.29
Osteoclasts promote the formation of hematopoietic stem cell niches in the bone marrow. J Exp Med (2012) 1.28
Molecular and functional characteristics of heart-valve interstitial cells. Philos Trans R Soc Lond B Biol Sci (2007) 1.27
Role of T and NK cells and IL7/IL7r interactions during neonatal maturation of lymph nodes. Proc Natl Acad Sci U S A (2006) 1.26
FHL2 inhibits the activated osteoclast in a TRAF6-dependent manner. J Clin Invest (2005) 1.25
Adenosine A(2A) receptor ligation inhibits osteoclast formation. Am J Pathol (2011) 1.21
Osteoclast progenitors reside in the peroxisome proliferator-activated receptor γ-expressing bone marrow cell population. Mol Cell Biol (2011) 1.20
The biology of progesterone receptor in the normal mammary gland and in breast cancer. Mol Cell Endocrinol (2011) 1.19
Modulating the intestinal immune system: the role of lymphotoxin and GALT organs. Gut (2004) 1.17
Genetic evidence for a role for Src family kinases in TNF family receptor signaling and cell survival. Genes Dev (2001) 1.17
Clinical development of anti-RANKL therapy. Arthritis Res Ther (2007) 1.17
RANK, RANKL and osteoprotegerin in bone biology and disease. Curr Rev Musculoskelet Med (2009) 1.17
A TNF receptor loop peptide mimic blocks RANK ligand-induced signaling, bone resorption, and bone loss. J Clin Invest (2006) 1.15
IL-1 receptor-associated kinase M is a central regulator of osteoclast differentiation and activation. J Exp Med (2005) 1.15
Regulation of NFATc1 in Osteoclast Differentiation. J Bone Metab (2014) 1.15
Role of periodontal pathogenic bacteria in RANKL-mediated bone destruction in periodontal disease. J Oral Microbiol (2010) 1.14
Complementary interplay between matrix metalloproteinase-9, vascular endothelial growth factor and osteoclast function drives endochondral bone formation. Dis Model Mech (2010) 1.13
Do RANKL inhibitors (denosumab) affect inflammation and immunity? Osteoporos Int (2010) 1.12
Interactions between immune and bone cells: new insights with many remaining questions. J Clin Invest (2000) 1.11
Erosive arthritis. Arthritis Res Ther (2007) 1.11
Natural killer cells trigger osteoclastogenesis and bone destruction in arthritis. Proc Natl Acad Sci U S A (2010) 1.11
Signaling networks that control the lineage commitment and differentiation of bone cells. Crit Rev Eukaryot Gene Expr (2009) 1.11
Interaction of bone morphogenetic proteins with cells of the osteoclast lineage: review of the existing evidence. Osteoporos Int (2007) 1.11
Osteoclast fusion and regulation by RANKL-dependent and independent factors. World J Orthop (2012) 1.11
Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL. J Biol Chem (2010) 1.10
Adenosine A(1) receptors regulate bone resorption in mice: adenosine A(1) receptor blockade or deletion increases bone density and prevents ovariectomy-induced bone loss in adenosine A(1) receptor-knockout mice. Arthritis Rheum (2010) 1.08
The role of TNF-receptor family members and other TRAF-dependent receptors in bone resorption. Arthritis Res (2000) 1.07
Transplantation of mesenchymal stem cells overexpressing RANK-Fc or CXCR4 prevents bone loss in ovariectomized mice. Mol Ther (2009) 1.06
Molecular mechanism of the bifunctional role of lipopolysaccharide in osteoclastogenesis. J Biol Chem (2009) 1.06
TAK1 is essential for osteoclast differentiation and is an important modulator of cell death by apoptosis and necroptosis. Mol Cell Biol (2012) 1.05
RANKL employs distinct binding modes to engage RANK and the osteoprotegerin decoy receptor. Structure (2012) 1.04
The role of T helper type 17 cells in inflammatory arthritis. Clin Exp Immunol (2009) 1.03
Adenosine and bone metabolism. Trends Endocrinol Metab (2013) 1.02
Osteoclasts and the immune system. J Bone Miner Metab (2009) 1.02
Differential effects of biologic versus bisphosphonate inhibition of wear debris-induced osteolysis assessed by longitudinal micro-CT. J Orthop Res (2008) 1.02
Breaking down bone: new insight into site-specific mechanisms of breast cancer osteolysis mediated by metalloproteinases. Genes Dev (2009) 1.00
Regulation of bone by the adaptive immune system in arthritis. Arthritis Res Ther (2011) 1.00
An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. Am J Pathol (2006) 1.00
Progesterone receptor and Stat5 signaling cross talk through RANKL in mammary epithelial cells. Mol Endocrinol (2013) 1.00
Interleukin-32 promotes osteoclast differentiation but not osteoclast activation. PLoS One (2009) 0.99
Marginal reticular cells: a stromal subset directly descended from the lymphoid tissue organizer. Front Immunol (2012) 0.99
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell (1998) 17.76
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell (1997) 15.96
Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell (1991) 14.89
Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A (1998) 12.61
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature (1999) 12.32
The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell (1994) 9.25
The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature (1990) 8.94
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature (1997) 8.59
osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev (1998) 7.81
TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev (1999) 6.93
Early lethality, functional NF-kappaB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice. Immunity (1997) 6.15
c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science (1994) 5.97
Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A (1999) 5.78
Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med (1997) 5.72
Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev (1997) 5.65
Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med (1996) 5.32
Characterization and regulation of RB6-8C5 antigen expression on murine bone marrow cells. J Immunol (1991) 5.02
TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem (1997) 4.61
The lymphotoxin beta receptor controls organogenesis and affinity maturation in peripheral lymphoid tissues. Immunity (1998) 4.56
Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology (1998) 4.29
Modulation of osteoclast differentiation. Endocr Rev (1992) 4.27
Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem (1998) 3.88
Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci U S A (1998) 3.60
TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med (1997) 3.59
Toward a molecular understanding of skeletal development. Cell (1995) 3.55
Control points in early T-cell development. Immunol Today (1993) 3.33
Advances in bone biology: the osteoclast. Endocr Rev (1996) 3.03
Developmental pathways of dendritic cells in vivo: distinct function, phenotype, and localization of dendritic cell subsets in FLT3 ligand-treated mice. J Immunol (1997) 2.89
The TRAF family of signal transducers mediates NF-kappaB activation by the TRANCE receptor. J Biol Chem (1998) 2.80
Pleiotropic effects of a null mutation in the c-fos proto-oncogene. Cell (1992) 2.78
Targeted disruption of TRAF3 leads to postnatal lethality and defective T-dependent immune responses. Immunity (1996) 2.70
RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun (1998) 2.62
Functions of CD40 on B cells, dendritic cells and other cells. Curr Opin Immunol (1997) 2.62
Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun N-terminal kinase. J Biol Chem (1998) 2.48
Activation of NF-kappaB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-kappaB-inducing kinase. Identification of a novel TRAF6 interaction motif. J Biol Chem (1999) 2.44
Osteopetrosis in mice lacking haematopoietic transcription factor PU.1. Nature (1997) 2.31
CD40 ligand-transduced co-stimulation of T cells in the development of helper function. Nature (1995) 2.23
Cross-linking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells. Immunity (1995) 2.17
Hematologic effects of flt3 ligand in vivo in mice. Blood (1996) 2.02
Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. J Immunol (1999) 1.96
TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells. J Immunol (1999) 1.95
The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-kappaB, a member of the TNFR superfamily. J Biol Chem (1998) 1.86
Cancer and bone. Endocr Rev (1998) 1.77
TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation. J Exp Med (1999) 1.67
Delayed hematopoietic development in osteopetrotic (op/op) mice. J Exp Med (1993) 1.62
OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. J Immunol (1998) 1.54
Cytokine regulation of secondary lymphoid organ development. Curr Opin Immunol (1998) 1.44
Deficiency of the Hck and Src tyrosine kinases results in extreme levels of extramedullary hematopoiesis. Blood (1996) 1.37
Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. Biochem Biophys Res Commun (1998) 1.33
Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone. Biochem Biophys Res Commun (1998) 1.33
Transforming growth factor-beta stimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells. J Biol Chem (1998) 1.31
Reverse signaling via CD30 ligand. J Immunol (1996) 1.22
Antigen-specific T lymphocytes regulate lipopolysaccharide-induced apoptosis of dendritic cells in vivo. J Immunol (1998) 1.22
Simultaneous demonstration of bone alkaline and acid phosphatase activities in plastic-embedded sections and differential inhibition of the activities. Histochemistry (1987) 1.12
Genetics of skeletogenesis. Dev Genet (1998) 1.08
Mice lacking c-fos have normal hematopoietic stem cells but exhibit altered B-cell differentiation due to an impaired bone marrow environment. Mol Cell Biol (1994) 1.06
TRANCE-RANK, a new signal pathway involved in lymphocyte development and T cell activation. J Exp Med (1999) 0.99
(Dichloromethylene)diphosphonate-induced impairment of T-lymphocyte function. Proc Natl Acad Sci U S A (1983) 0.98
The Ensembl genome database project. Nucleic Acids Res (2002) 40.87
Ensembl 2009. Nucleic Acids Res (2008) 25.38
Ensembl 2008. Nucleic Acids Res (2007) 20.67
Ensembl 2007. Nucleic Acids Res (2006) 20.10
Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States. Science (1999) 18.55
Ensembl 2005. Nucleic Acids Res (2005) 15.13
SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins. Science (1991) 12.93
Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med (2001) 12.38
Ensembl 2002: accommodating comparative genomics. Nucleic Acids Res (2003) 12.26
Ensembl 2004. Nucleic Acids Res (2004) 11.88
Ensembl 2006. Nucleic Acids Res (2006) 11.66
A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature (1997) 10.14
Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med (2000) 9.78
Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. J Exp Med (1994) 8.97
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature (1997) 8.59
Natural history of acute coronary heart attacks. A community study. Br Heart J (1972) 8.55
Stimulation of homologous recombination through targeted cleavage by chimeric nucleases. Mol Cell Biol (2001) 6.68
Pathology of fatal West Nile virus infections in native and exotic birds during the 1999 outbreak in New York City, New York. Vet Pathol (2000) 6.46
Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen (2000) 6.24
CD8alpha+ and CD8alpha- subclasses of dendritic cells direct the development of distinct T helper cells in vivo. J Exp Med (1999) 6.06
Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J (1994) 5.69
Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc Natl Acad Sci U S A (1999) 5.66
Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis. Clin Infect Dis (1994) 5.44
Redesigning health care. BMJ (2001) 5.43
Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med (1996) 5.32
Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med (1994) 5.20
Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood (2000) 5.06
A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science (1990) 4.90
Molecular and biological characterization of a murine ligand for CD40. Nature (1992) 4.83
Tobacco and cancer: recent epidemiological evidence. J Natl Cancer Inst (2004) 4.83
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med (1996) 4.70
The murine interleukin-4 receptor: molecular cloning and characterization of secreted and membrane bound forms. Cell (1989) 4.48
Initiation of liver growth by tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necrosis factor receptor. Proc Natl Acad Sci U S A (1997) 4.33
TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J Immunol (1998) 4.32
Activation of the mouse cellular Harvey-ras gene in chemically induced benign skin papillomas. Nature (1984) 4.28
Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis. J Clin Microbiol (1994) 4.27
Cloning of the human and murine interleukin-7 receptors: demonstration of a soluble form and homology to a new receptor superfamily. Cell (1990) 4.15
TB policy and the badger culling trials. Vet Rec (2006) 4.14
Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med (2000) 4.14
Src homology region 2 domains direct protein-protein interactions in signal transduction. Proc Natl Acad Sci U S A (1990) 4.13
Molecular cloning of mast cell growth factor, a hematopoietin that is active in both membrane bound and soluble forms. Cell (1990) 3.98
The clinical and laboratory diagnosis of Trichomonas vaginalis infection. Sex Transm Dis (1981) 3.89
TB policy and the badger culling trials. Vet Rec (2006) 3.84
Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J Biol Chem (1998) 3.83
The Social Functioning Scale. The development and validation of a new scale of social adjustment for use in family intervention programmes with schizophrenic patients. Br J Psychiatry (1990) 3.75
Systematic review of multidisciplinary interventions in heart failure. Heart (2005) 3.68
Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet (2002) 3.67
Management of women with mild and moderate cervical dyskaryosis. BMJ (1994) 3.65
Identification and cloning of a novel IL-15 binding protein that is structurally related to the alpha chain of the IL-2 receptor. EMBO J (1995) 3.59
Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nat Genet (1996) 3.56
Phenotypic and functional characterization of mice that lack the type I receptor for IL-1. J Immunol (1997) 3.56
cDNA expression cloning of the IL-1 receptor, a member of the immunoglobulin superfamily. Science (1988) 3.56
Human anergic/suppressive CD4(+)CD25(+) T cells: a highly differentiated and apoptosis-prone population. Eur J Immunol (2001) 3.53
The "redisorganisation" of the NHS. BMJ (2001) 3.52
Cloning of the murine thymic stromal lymphopoietin (TSLP) receptor: Formation of a functional heteromeric complex requires interleukin 7 receptor. J Exp Med (2000) 3.51
Effect of low-level body burdens of lead on the mental development of children: limitations of meta-analysis in a review of longitudinal data. Arch Environ Health (1992) 3.42
Inhibition of murine B and T lymphopoiesis in vivo by an anti-interleukin 7 monoclonal antibody. J Exp Med (1993) 3.38
Interleukin 10 and interferon gamma regulation of experimental Trypanosoma cruzi infection. J Exp Med (1992) 3.34
Humoral immune responses in CD40 ligand-deficient mice. J Exp Med (1994) 3.32
Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes. J Immunol (1993) 3.29
A small viral RNA is required for in vitro packaging of bacteriophage phi 29 DNA. Science (1987) 3.29
Performance of focus ELISA tests for herpes simplex virus type 1 (HSV-1) and HSV-2 antibodies among women in ten diverse geographical locations. Clin Microbiol Infect (2004) 3.27
Role of lymphotoxin and the type I TNF receptor in the formation of germinal centers. Science (1996) 3.24
Cervical screening in Perth and Kinross since introduction of the new contract. BMJ (1991) 3.20
A low resolution structure for the histone core of the nucleosome. Nature (1980) 3.17
Bcl-2 can rescue T lymphocyte development in interleukin-7 receptor-deficient mice but not in mutant rag-1-/- mice. Cell (1997) 3.13
Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment. Am J Trop Med Hyg (1995) 3.08
Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J Exp Med (1999) 3.07
Public health gets a boost in NHS streamlining. BMJ (1994) 3.03
Cloning, sequence and expression of human interleukin-2 receptor. Nature (1985) 3.02
WEIL'S DISEASE (LEPTOSPIROSIS): A CLINICAL AND BACTERIOLOGICAL STUDY OF NINETEEN CASES OCCURRING CHIEFLY AMONG FISH WORKERS. Br Med J (1934) 2.99
The dynamics of chromosome evolution in birds and mammals. Nature (1999) 2.95
Mast cell growth factor maps near the steel locus on mouse chromosome 10 and is deleted in a number of steel alleles. Cell (1990) 2.95
Functional analysis of the domain structure of tumor necrosis factor-alpha converting enzyme. J Biol Chem (2000) 2.92
Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet (1998) 2.90
Cytokine-mediated regulation of chronic intestinal helminth infection. J Exp Med (1994) 2.90
Measurement of muscle mass in humans: validity of the 24-hour urinary creatinine method. Am J Clin Nutr (1983) 2.89
Developmental pathways of dendritic cells in vivo: distinct function, phenotype, and localization of dendritic cell subsets in FLT3 ligand-treated mice. J Immunol (1997) 2.89
Women prefer hospital births. BMJ (1992) 2.88
Recombinant human CD40 ligand stimulates B cell proliferation and immunoglobulin E secretion. J Exp Med (1992) 2.86